title: ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
abstract: Sixty consecutive patients with untreated acute leukemia alternately received either ABO-matched or ABO-mismatched random-donor platelet transfusions prepared from pooled platelet concentrate stored for 1 to 3 days. Patients were assigned randomly to receive matched or mismatched platelets as their first transfusion, and the first four transfusions were analyzed. In 40 evaluable patients, there was no significant difference (paired t test) between the 10-minute posttransfusion corrected count increments (CCI) of the initial transfusions of matched and mismatched platelets. In contrast, the second matched transfusion was significantly better than the second mismatched transfusion. This effect of ABO compatibility was particularly pronounced in a subset of patients. Six patients in whom mismatched transfusions were consistently inferior to matched transfusions had either a significant increase in anti-A or -B isoagglutinin titers following the first transfusion or elevated titers before or at the conclusion of the study. Conversely, in five patients in whom there was no apparent effect of ABO mismatching, only one had an increase in isoagglutinin titer. Platelet survival was not altered as the ratio of 18-hour to 10-minute posttransfusion CCl was 0.6 for both matched and mismatched platelet transfusions. These data demonstrate that ABO compatibility can affect the results of random-donor platelet transfusions and that patients who experience poor increments from ABO-mismatched platelets may benefit from a trial of ABO-compatible platelets before the initiation of HLA-matched platelet transfusion.
authors.affiliation: Division of Hematologic Malignancies, University of Maryland Cancer Center, Baltimore.
authors.forename: E J
authors.initials: EJ
authors.lastname: Lee
authors.forename: C A
authors.initials: CA
authors.lastname: Schiffer
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility / Q000097:blood*; D001792:Blood Platelets / Q000502:physiology; D001803:Blood Transfusion; D002470:Cell Survival; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007518:Isoantibodies / Q000096:biosynthesis; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000628:therapy; D011897:Random Allocation; D013921:Thrombocytopenia / Q000097:blood / Q000628:therapy; D065227:Transfusion Reaction
chemical_list: D000017:ABO Blood-Group System; D007518:Isoantibodies